T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively ...

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...